Now I have all the information I need. Let me write the consolidated review.

**Round 1 bracket:** Based on calibration search, the paper clearly sits above the weak band (<3.5) and the middle band (3.5–7.5) with comparable papers scoring 5.5–6.5. It does not reach the >7.5 band (which includes spotlight/oral papers). Initial bracket: 5.5–7.0.

**Round 2 narrowing:** I examined papers in the 5.5–7.5 range and read several in full. The most comparable anchors (accepted posters at medical/classification venues at ~5.75–6.5) show that this paper has a novel architecture, solid results on two benchmarks, and reasonable ablation, placing it near the upper end of the middle band. The weaknesses (missing backbone baseline, no proposal visualization) are real but not fatal. Score: 6.5.

**Calibration anchors consulted:** FUgrjq2pbB (6.5), Lv9KZ5qCSG (5.5), ZBH4fqQwJQ (4.75), t1J2CnDFwj (5.75), PacBhLzeGO (6.25), 6NO5UVWvo6 (4.5), s5epFPdIW6 (7.0), ozZG5FXuTV (6.0), H9UnNgdq0g (6.25), otHZ8JAIgh (7.25).

Now the review:

## Summary
2-3 sentence summary...

---

## Summary

This paper proposes an end-to-end framework for multi-view diabetic retinopathy (DR) grading that internally generates lesion proposals (GALP module) and fuses them across views via a gated mixture-of-experts module with Top-K weighted cross-view attention (LGRF module). The central claim is that self-generated proposals can substitute for costly external lesion/vessel annotations, achieving competitive or state-of-the-art accuracy on two multi-view benchmarks (MFIDDR and DRTiD) while preserving end-to-end training.

## Strengths

1. **Self-generated lesion proposals achieve strong performance without external annotations.** Table 1 shows that the lesion-free variant reaches 83.9% accuracy on MFIDDR, outperforming all end-to-end baselines (best: ETMC at 81.5%) and matching or exceeding several externally-informed methods (CVSA with vessel masks at 82.6%, LFMVDR with lesion at 82.2%). This directly supports the core claim that internally derived cues can substitute for expert annotations.

2. **Cross-view fusion with gated expert routing is empirically necessary.** The ablation study (Table 4) shows that removing the expert pool drops accuracy from 83.9% to 82.6% and removing LGRF entirely drops it to 82.3%. These systematic degradations confirm that the gated MoE and Top-K weighted attention are functionally critical to the reported gains, not architectural ornamentation.

3. **SOTA on a second benchmark without external side information.** On DRTiD (Table 3), the end-to-end variant achieves 76.0% accuracy, surpassing CrossFIT (75.6%) which requires optic disc and macula coordinates. This cross-dataset generalization strengthens the case for the method's annotation-free advantage.

4. **When external annotations are available, the framework seamlessly integrates them to set new SOTA.** The "with lesion" variant achieves 84.6% accuracy, 72.3% Kappa, and 84.4% F1 on MFIDDR—the best reported across all methods. This dual capability (annotation-free vs. annotation-integrated) is a practical strength not demonstrated by prior end-to-end or externally-informed methods in isolation.

5. **Systematic hyperparameter analysis.** Figure 3 explores retention ratio (α), number of activated experts (K₂), and total experts (M), showing clear optimal values (α=0.5, K₂=2, M=6) with non-trivial degradation at other settings. This indicates the authors did not overfit to a lucky configuration.

## Weaknesses

### Fatal
None.

### Major

1. **Missing backbone-equivalent baseline for isolating module contributions.** The paper does not include a simple multi-view baseline using the *same* Swin-B backbone with a straightforward fusion strategy (e.g., process each view through Swin-B, apply global average pooling per view, concatenate, and classify). All end-to-end baselines (MVCINN, MVCNN variants, ETMC, RETFound) use different backbones. The ablation study shows that the degraded variants (w/o GALP: 82.7%, w/o LGRF: 82.3%) still outperform the best end-to-end baseline (ETMC: 81.5%), but neither degraded variant is a pure backbone baseline—w/o GALP still uses LGRF on all tokens, and w/o LGRF still uses GALP proposals. Without a vanilla Swin-B multi-view baseline, we cannot precisely quantify how much of the 2.4% gap between the full method (83.9%) and ETMC (81.5%) is due to the proposed modules versus the stronger backbone alone. The contribution is likely real (the ablation gaps support this), but the evidence is weaker than it should be for a central claim.

2. **No qualitative evidence that proposals correspond to actual lesions.** The paper repeatedly refers to "lesion proposals" derived from grade-conditioned evidence maps (GEMs), yet provides no visualization or analysis showing that the selected regions contain microaneurysms, hemorrhages, exudates, or other DR lesions. The assumption that grade-discriminative regions are lesion regions is plausible but unverified. Given that the method is motivated by recovering small, low-contrast lesions (as stated in the abstract), and that interpretability is claimed as an advantage (Section 1: "superior robustness and interpretability"), at least qualitative validation should be provided. The MFIDDR dataset includes lesion segmentation masks—these could be used to verify co-localization.

### Minor

3. **Incomplete ablation granularity.** The ablation study removes entire modules (GALP, Experts, LGRF) but does not isolate individual sub-components. For example, GALP includes both an auxiliary classification loss and the Top-K proposal selection mechanism; removing GALP removes both simultaneously, so the relative contribution of the auxiliary supervision versus the spatial selection is unclear. Similarly, the expert pool is removed alongside the routing mechanism. A finer-grained ablation (e.g., w/o auxiliary loss but keep proposal selection, or uniform expert weighting instead of routing) would clarify the source of the gains.

4. **Adjacent-view-only fusion is not justified or ablated.** The method fuses each view only with its cyclically adjacent neighbor (view i with view i+1, modulo N). For four-view MFIDDR, this means each view connects to only one other view. The paper offers no justification for this restriction and does not ablate alternatives (e.g., fusing with all other views or using a learnable graph structure). Non-adjacent views may contain complementary lesion information that is lost under this design.

5. **No error bars or confidence intervals.** All reported results are single-run point estimates. For a medical grading task where variance across runs matters (especially for rare severe grades), the absence of any variance quantification (e.g., mean and std over 3–5 seeds) makes it difficult to assess whether observed differences are statistically significant.

### Trivial
None.

## Nice-to-Haves

- Report FLOPs, parameter counts, and inference time compared to baselines to clarify the method's practical cost.
- Discuss the low Grade 4 F1 scores (36–51%, vs. ≤45% for most baselines—Table 2) as a failure case analysis.
- Clarify how the patch size q (7 for MFIDDR, 8 for DRTiD) was chosen and whether it varies across stages.
- The MoE routing uses the mean-pooled representation of current-view tokens (Eq. 9); discussing why spatial information is discarded here would be helpful.

## Removed Points

- **"Equation (3) notation is confusing"**: Minor notation observation; does not affect the paper's correctness or clarity in any meaningful way. Removed.
- **"Top-K weighted cross-view attention description is convoluted; figure is small"**: Subjective presentation preference, not a substantive weakness. Removed.
- **"Retention ratio α=1.0 corresponds to a dense fusion baseline"**: The paper already reports α=1.0 as one setting in Figure 3 and discusses degradation at that setting. The harsh critic's point about testing statistical significance of the drop is a nice-to-have, not a weakness. Removed.
- **"If external annotations add so little, what is the advantage of complex GALP?"**: This misinterprets the paper—the "with lesion" variant adds only modest further gains because GALP already captures the useful signal, which is a positive finding for the method. Removed.
- **"The method is complex but gains are small (max 1.6% drop)"**: The 1.6% gap from 83.9% to 82.3% (w/o LGRF) is a clear, non-trivial gap in medical classification. Removed as an unfair characterization.
- **Strength Finder strength #4**: "Thorough hyperparameter analysis demonstrates design robustness"—this is kept as valid because it is specific and grounded in Figure 3. Retained in main review.

## Novel Insights

The harsh critic correctly identifies a structural gap—the missing backbone-equivalent baseline—that weakens the paper's central attribution claim. However, the critic's framing overstates the severity: even the degraded variants (w/o GALP, w/o LGRF) outperform all existing end-to-end baselines, suggesting the Swin-B backbone alone does not explain the full gain. The more interesting unresolved question is whether the *proposal selection* or the *auxiliary supervision* drives the improvement, and whether the proposals actually localize lesions—neither of which is resolved by the current experiments. The Strength Finder's emphasis on the cross-dataset generalization (DRTiD) is well-placed: outperforming CrossFIT *without* requiring optic disc/macula coordinates is the cleanest evidence for the paper's core claim, as it benchmarks directly against a method using external cues on its own preferred dataset.

## Suggestions

1. **Add a Swin-B + GAP + concat baseline** to all comparison tables. This single experiment would resolve the most significant attribution concern.
2. **Visualize the proposals** on 3–5 examples from MFIDDR: overlay the grade-conditioned evidence maps on fundus images, mark the top-K selected regions, and compare against the available lesion segmentation masks.
3. **Expand the ablation** by separating the auxiliary loss from the proposal selection mechanism (e.g., full GALP vs. GALP w/o aux loss vs. GALP w/o proposal selection).
4. **Report means and stds** over at least 3 random seeds for the main results and key ablations.

## Score and Decision

MY FINAL SCORE: <score>6.5</score>
MY FINAL DECISION: <decision>Accept</decision>